Finerenone is a non-steroidal mineralocorticoid receptor antagonist used to treat chronic kidney disease (CKD) associated with type 2 diabetes [1]. It works by blocking the effects of aldosterone, a hormone that can contribute to inflammation and fibrosis in the kidneys [2].
How does Finerenone work in the kidneys?
Finerenone reduces inflammation and fibrosis in the kidneys by blocking the mineralocorticoid receptor [2]. This action counteracts the negative effects of excessive aldosterone, which can lead to kidney damage in individuals with type 2 diabetes [2]. The drug has demonstrated a reduction in cardiovascular events and kidney disease progression in eligible patients [3].
What are the approved uses for Finerenone?
Finerenone is approved for the treatment of adults with chronic kidney disease (CKD) who also have type 2 diabetes [1]. This indication is based on clinical trial data showing benefits in slowing the progression of kidney disease and reducing cardiovascular risk [3].
When does Finerenone patent expire?
The patent landscape for finerenone indicates that its primary patent protections are expected to expire around 2034 [4]. This timeframe is crucial for understanding when generic versions of the drug might become available [4].
What are the potential side effects of Finerenone?
Common side effects associated with finerenone include hyperkalemia (high potassium levels), hypotension (low blood pressure), and hyponatremia (low sodium levels) [1]. Patients taking finerenone require regular monitoring of their potassium levels [3].
How does Finerenone compare to other CKD treatments?
Finerenone offers a distinct mechanism of action compared to other CKD treatments by directly targeting the mineralocorticoid receptor. While other treatments may focus on blood sugar control or blood pressure management, finerenone addresses inflammation and fibrosis pathways. Clinical studies have shown finerenone to be effective in reducing the risk of adverse kidney and cardiovascular outcomes in patients with type 2 diabetes and CKD [3].
Where can I find more information on Finerenone patents?
DrugPatentWatch.com provides detailed information on drug patents, including those for finerenone. Their resources can help track patent expiry dates and understand the intellectual property surrounding the medication [4].
What clinical trials support Finerenone's use?
The approval and understanding of finerenone are supported by significant clinical trials, including the FIDELIO-DKD and FIGARO-DKD studies [3]. These trials demonstrated finerenone's efficacy in reducing the risk of kidney failure and cardiovascular events in patients with CKD and type 2 diabetes [3].
Who manufactures Finerenone?
Finerenone is manufactured by Bayer [1].
What are the risks of high potassium levels with Finerenone?
Hyperkalemia, or high potassium levels, is a significant risk associated with finerenone therapy. This can lead to serious cardiac arrhythmias and other health complications. Regular monitoring of serum potassium is essential for patients receiving finerenone [3].
---
Cited Sources:
1. https://www.drugs.com/finerenone.html
2. https://www.bayer.com/en/newsroom/press-releases/news-details/2021/bayer-announces-us-fda-approval-of-kerendia-finerenone-tablets-for-the-treatment-of-chronic-kidney-disease-ckd-associated-with-type-2-diabetes-t2d/
3. https://www.nejm.org/doi/full/10.1056/NEJMoa2025845
4. https://drugpatentwatch.com/drug/finerenone